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Introduction
Red blood cell (RBC) transfusions are widely used worldwide in 
primary health care in less developed and newly industrialized coun-
tries as well as for high-performance procedures in health care of 
high-income countries. Improved survival due to RBC transfusions 
has been shown in specific situations such as in severe malaria-in-
duced anemia in children with a hemoglobin (Hb) concentration of 
< 39 g/l or an Hb < 47 g/l with concomitant respiratory distress [1–
3]. RBC transfusions also improve survival of elderly patients under-
going noncardiac surgery with a preoperative Hb < 80 g/l [4]. In ad-
dition, the European Trauma Treatment Guidelines recommend 
maintaining an Hb level of 70–90 g/l in severely injured patients by 
cell salvage, if possible, and RBC transfusions, if necessary [5].
However, RBC transfusions have also been shown to result in 
an increased mortality, length of hospital stay, organ dysfunction 
(lung, kidney, heart), infections, transfusion reactions, and huge 
costs [6, 7]. Therefore, a targeted use of RBC transfusion is manda-
tory, including evidence-based RBC transfusion triggers.
Defining the critical transfusion trigger in patients is not trivial. 
However, understanding the underlying physiological response 
and compensatory mechanisms during progressive anemia may be 
one approach to find the critical Hb level at which a RBC transfu-
sion would be necessary to avoid organ dysfunction or whole or-
ganism damage [8]. Another approach is to analyze outcome stud-
ies assessing the impact of different Hb transfusion triggers on 
clinically relevant outcomes such as mortality, morbidity, and the 
need for advanced life support. In this review we limit our analysis 
for both approaches to adult patients.
Last but not least only focusing on Hb transfusion triggers is an 
insufficient approach to the problems of RBC transfusion, patient 
safety, and outcome. The more holistic approach to patient safety 
and outcome is the concept of patient blood management which 
aims at improving outcome by correcting the three main factors 
resulting in adverse patient outcome, i.e., preoperative anemia [9, 
10], perioperative RBC loss [11, 12], and RBC transfusions [6, 13].
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Summary
Liberal versus restrictive red blood cell (RBC) transfusion 
triggers have been debated for years. This review illus-
trates the human body’s physiologic response to acute 
anemia and summarizes the evidence from prospective 
randomized trials (RCTs) for restrictive use of RBC trans-
fusions in high-risk patients. During progressive anemia, 
the human body maintains the oxygen delivery to the 
tissues by an increase in cardiac output and peripheral 
oxygen extraction. Seven RCTs with a total of 5,566 high-
risk patients compared a restrictive hemoglobin (Hb) 
transfusion trigger (Hb < 70 or < 80 g/l) with a liberal Hb 
transfusion trigger (Hb < 90 or < 100 g/l). Unanimously 
these studies show non-inferiority, safety, and a signifi-
cant reduction in RBC transfusions in the restrictive 
groups. In one RCT mortality was higher in the liberal Hb 
transfusion group, and in two additional RCTs mortality 
of subgroups or after risk adjustment was significantly 
higher in the liberal Hb transfusion trigger groups. Con-
clusion: Strong RCT evidence suggests the safety of re-
strictive transfusion triggers. As a consequence, an Hb 
transfusion trigger of <70 g/l is recommended for high- 
risk patients.
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Physiology of Progressive Anemia
Oxygen delivery and off-loading to the tissues is vital for our 
organism to maintain energy production by oxidation of glucose to 
carbon dioxide and water. In the mitochondria stepwise metabo-
lism of the glucose molecule leads to the production of adenosine 
triphosphate (ATP). ATP hydrolysis to adenosine diphosphate by 
ATPases is an ubiquitary process to sustain cellular enzyme energy 
requirements. In aerobic conditions, one glucose molecule is me-
tabolized to 30 molecules of ATP, whereas in anaerobic or hypoxic 
circumstances the glucose degradation stops at the level of 3 car-
bon atoms with lactate as an end product, resulting in an overall 
gain of 2 molecules of ATP only. 
Oxygen delivery (DO2) is the product of cardiac output and ar-
terial oxygen content (CaO2). CaO2 is the sum of Hb-bound oxy-
gen (Hb × 1.34 × SaO2) and plasma-dissolved oxygen (PaO2 × F; 
F = 0.0031 if PaO2 is in mm Hg, F = 0.0233 if PaO2 is in kPa), 
whereby under atmospheric conditions the Hb-bound part is far 
greater (approximately 98%) than the plasma-dissolved part [8]. 
Therefore, oxygen delivery depends critically on cardiac output, 
Hb concentration, and SaO2. Hence tissue hypoxia (insufficient 
oxygen delivery) can be due to ischemia (reduction in cardiac out-
put or blood supply), hypoxia (decrease of SaO2), toxins (blocking 
Hb oxygen binding), and anemia. 
Blood loss and concomitant crystalloid or colloid infusion re-
sults in normovolemic hemodilution, i.e. normovolemia with a de-
creased Hb concentration. Physiologically, cardiac output increases 
to compensate the lower CaO2 at low Hb concentrations in order 
to maintain oxygen delivery. The increase in cardiac output is pri-
marily due to an increase in stroke volume and inotropy and only 
secondarily due an increase in heart rate. O2 extraction increases 
simultaneously favoring O2 off-loading to the tissue. During ex-
treme anemia and hemorrhagic shock, cardiac output is addition-
ally redistributed to preserve blood and oxygen delivery to the vital 
organs (heart and brain) [14].
When hemoglobin concentration is lowered to a critical value 
Hb(crit), O2 off-loading to the tissue is no more sufficient to main-
tain O2 consumption. The Hb(crit) can be experimentally deter-
mined by measuring the start of the decline of whole body or organ 
oxygen uptake. As a consequence and without further treatment, 
animals die within 3 h after reaching the Hb(crit) [15]. By increas-
ing the inspired O2 concentration, an exaggerated level of hemodi-
lution with a lower Hb(crit) can be reached [16].
Acute anemia tolerance differs among organs. In anesthetized 
pigs, cellular signs of hypoxia in the kidney and skeletal muscle de-
veloped at significantly higher Hb concentrations than in the heart, 
brain, and liver [17]. Last but not least, anesthetic measures such as 
deep neuromuscular blockade [18], application of norepinephrine 
to treat severe arterial hypotension [19], and induction of hypo-
thermia [20] can increase anemia tolerance. From a physiologic 
point of view, anemia tolerance thus is quite remarkable. Interest-
ingly, the human body responds very similarly, and its compensa-
tory capacity is largely maintained even in patients with cardiovas-
cular diseases and also in the elderly [8, 14].
Prospective Randomized Studies on the Effect of 
Restrictive versus Liberal Hemoglobin Transfusion 
Triggers
The first prospective randomized study compared the effect of 
an Hb transfusion trigger of <70 g/l with that of a transfusion trig-
ger of <90 g/l in general intensive care unit (ICU) patients (n = 
838) [21]. 30-day mortality was not significantly different between 
the groups, but there was a trend (p = 0.10) towards better survival 
in the restrictive group. In two prospectively defined subgroups, in 
patients younger than 55 years and in patients with APACHE II 
scores of ˯20, however, survival was significantly better in the re-
strictive transfusion groups. In addition, hospital mortality was 
lower in the restrictive group (22.2 vs. 28.1%; p = 0.05), and there 
was significantly less multiple organ dysfunction in the restrictive 
versus the liberal RBC transfusion group [21]. 
In the next prospective randomized study, the effect of an Hb 
transfusion trigger of <80 g/l was compared with that of a transfu-
sion trigger of <100 g/l in patients (n = 502) undergoing cardiac 
surgery [22]. Primary outcome, a composite of mortality and major 
morbidity (cardiogenic shock, acute respiratory distress syndrome, 
or acute renal injury requiring renal replacement), was similar in 
both groups. However, when analyzed independently of group as-
signment, each RBC transfusion significantly increased the risk of 
30-day mortality or clinical complications by 20% (hazard ratio 
1.2, 95% CI 1.1–1.4; p = 0.002).
Also in elderly high-risk patients (n = 2,016) with hip fracture 
and signs of coronary artery disease and a postoperative Hb < 100 
g/l, the effect of a liberal Hb transfusion trigger of <100 g/l was 
compared with a restrictive transfusion trigger (combination of 
well-defined symptoms of anemia or an Hb < 80 g/l) in a prospec-
tive randomized study [23]. 60-day mortality was similar in the re-
strictive (6.6%) and the liberal group (7.6%), and also the inability 
to walk was similar between the groups. The authors subsequently 
analyzed long-term survival over a median of 3 years. There were 
432 deaths in the liberal group and 409 deaths in the restrictive 
group (hazard ratio 1.09, 95% CI 0.95–1.25; p = 0.21). In only 1 of 
18 subgroup analyses there was a trend (p < 0.10) towards a higher 
or lower mortality in patients randomized to the liberal Hb trans-
fusion trigger. Interestingly, a trend towards a higher mortality was 
observed in patients with coronary artery disease randomized to 
the liberal Hb transfusion trigger (hazard ratio 1.26, 95% CI 1.04–
1.54; p = 0.06). Causes of death did not differ between groups 
(p = 0.99) [24]. 
In patients (n = 912) with acute upper gastrointestinal bleeding, 
the effect of an Hb transfusion trigger of <70 g/l was compared 
with that of an Hb transfusion trigger of <90 g/l in a prospective 
randomized fashion [25]. 45-day survival was significantly better in 
the restrictive (95%) than in the liberal group (91%), with a hazard 
ratio for death of 0.55 (95% CI 0.33–0.92; p = 0.02) favoring the 
restrictive RBC transfusion regimen. In addition, the rate of re-
bleeding was significantly lower in the restrictive than in the liberal 
group (10 vs. 16%; p = 0.01); moreover, less emergency surgery was 
required (2 vs. 6%; p = 0.04), complication rate was lower (40 vs. 
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48%; p = 0.02) and length of hospital stay was shorter (9.6 vs. 11.5 
days; p = 0.01) in the restrictive versus the liberal group.
In a feasibility study including 100 patients, Walsh et al. [26] 
studied the effect of a restrictive Hb transfusion trigger (Hb < 70 
g/l) vs. a liberal Hb transfusion trigger (Hb < 90 g/l) in patients 
older than 55 years who were ventilated mechanically for at least 4 
days in the ICU. The Hb level was significantly different between 
the groups during the study period of 14 days (Hb difference = 14 
g/l, 95% CI 1.2–1.6 g/l; p < 001). Fewer patients (–22%) randomized 
to the restrictive group were transfused and received a median of 1 
RBC transfusions less (p = 0.002). Ventilation-free days tended to 
be higher (38 days) in the restrictive group than in the liberal group 
(27 days), and also 180-day mortality tended to be lower in the re-
strictive group (37%) when compared to the liberal group (55%). 
While these differences did not reach statistical significance, this 
study clearly shows that a liberal transfusion regimen did not facili-
tate weaning nor influenced mortality favorably.
Recently the effect of erythropoietin (yes/no) and Hb trans-
fusion trigger (Hb < 70 g/l vs. Hb < 100 g/l) was compared in a 
prospective randomized factorial design (2 × 2) study in patients 
(n = 200) with acute traumatic brain injury [27]. The primary out-
come was favorable neurologic outcome as assessed by the Glas-
gow Outcome Score at 6 months. Multiple secondary outcomes 
were also assessed prospectively. The administration of erythropoi-
etin did not affect any outcome, and there was also no interaction 
between erythropoietin administration and the Hb transfusion 
 levels. Glasgow Outcome Score at 6 months was similar in both 
transfusion groups, but disability tended to be less (5 vs. 8; p = 
0.06) in the restrictive vs. the liberal group, and there were fewer 
thrombotic complications in the restrictive vs. the liberal group (8 
vs. 22%; p = 0.009).
Last but not least, the effect of a restrictive (Hb < 70 g/l) vs. a 
liberal (Hb < 90 g/l) transfusion regimen on outcome of patients 
(n = 998) with septic shock has been compared in a prospective 
ran domized study [28]. The primary outcome was 90-day mortal-
ity; secondary outcome was the need for advanced support meas-
ures (vasopressors, inotropes, mechanical ventilation, and renal-
replacement therapies) within the first 28 days. Mortality and the 
need for advanced support measures were similar between both 
groups.
Interestingly, in all studies mentioned in this section, the lack of 
efficacy and the side effect profile of liberal transfusion regimens 
do not appear to be related to the populations studied, irrespective 
of the facts whether leukoreduced or non-leukoreduced RBCs were 
transfused, how long the RBCs were stored before use (where this 
information is available), or whether RBCs had been transfused 
prior to study enrollment or not (table 1).
Meta-Analyses
There are two important meta-analyses that need to be pre-
sented here. In 2012 Carson et al. [29] analyzed 19 prospective ran-
domized trials comparing restrictive and liberal transfusion regi-
mens, including a total of 6,264 patients. This meta-analysis clearly 
showed that a restrictive transfusion regimen reduced the need for 
RBC transfusions by 39% (relative risk 0.61, 95% CI 0.52–0.73), 
hospital mortality by 23% (relative risk 0.77, 95% CI 0.62–0.95), 
and infections by 19% (relative risk 0.81, 95% CI 0.66–1.00). 30-
day mortality (–15%) just missed statistical significance (relative 
risk 0.85, 95% CI 0.70–1.03). However, the last 2 big prospective 
randomized studies in patients with upper gastrointestinal bleed-
Table 1. Prospective randomized studies on the effect of restrictive versus liberal hemoglobin transfusion triggers 
Study population Leukoreduction Storage duration 
(median), days
RBC transfusion before enrollment
Hébert et al. 1999 [21] general ICU  
(n = 838)
no unknown 2.5 U/patient (restrictive) 
2.3 U/patient (liberal)
Hajjar et al. 2010 [22] cardiac surgery  
(n = 502)
no  3 none
Carson et al. 2011 [23] hip fracture  
(n = 2,016)
90% 22 1.8 U/transfused patient (restrictive) 
1.8 U/transfused patient (liberal)
Villanueva et al. 2013 [25] upper GI bleeding  
(n = 912)
100% 15 none
Walsh et al. 2013 [26] mechanical ventilation  
(n = 100)
no 21 71% with a median of 3 U/patient (restrictive) 
67% with a median of 2 U/patient (liberal)
Robertson et al. 2014 [27] traumatic brain injury  
(n = 200)
100% unknown none
Holst et al. 2014 [28] septic shock  
(n = 998)
100% unknown 10% with a median of 2 U/transfused patient (restrictive) 
12% with a median of 2 U/transfused patient (liberal)
ICU = Intensive care unit; U = unit; GI = gastrointestinal.
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ing (n = 912) and with septic shock (n = 998) were not yet in-
cluded, and since both had either a significant effect or a trend to-
wards a better survival in the restrictive groups it may be expected 
that an updated meta-analysis including these two studies would 
show a long-term survival benefit for patients treated according to 
a restrictive transfusion regimen.
The second meta-analysis was performed in 2014 by Rohde et 
al. [30] including 18 prospective randomized studies with 7,593 pa-
tients. They found that a restrictive RBC transfusion regimen re-
sulted in a reduction of postoperative infections by 12% (relative 
risk 0.88, 95% CI 0.78–0.99; p = 0.033) and of postoperative serious 
infections by 18% (relative risk 0.82, 95% CI 0.72–0.95; p = 0.006). 
Interestingly, when the meta-analysis was restricted to studies with 
only leukoreduced RBCs, the reduction of all types of infections 
decreased by 20% (relative risk 0.80, 95% CI 0.67–0.95; p = 0.001). 
This clearly shows that the infection risk due to RBC transfusion is 
neither eliminated nor reduced by leukoreduction.
Hemoglobin Transfusion Trigger
The combined evidence thus suggests that a liberal RBC trans-
fusion regimen is not beneficial but potentially harmful for the pa-
tients. In high-risk patients, such as ICU patients, elderly patients 
with coronary artery disease, patients with upper gastrointestinal 
bleeding, patients with traumatic brain injury and patients with 
septic shock, an Hb transfusion trigger of <70 g/l is safe and helps 
avoiding transfusion-related complications. The <70 g/l Hb trans-
fusion trigger thus is established as the ‘new normal’ in all critical 
patients [31] with the potential exception of patients with an acute 
coronary syndrome in which an Hb transfusion trigger of <80 g/l 
might be adequate [32].
Remarkably, Goodnough et al. [33] succeeded in implementing 
a restrictive transfusion regimen in their center by an intelligent 
blood ordering system. The percentage of RBC transfusions at an 
Hb > 80 g/l thereby decreased from approximately 60 to below 
30%. In a subsequent study, Goodnough et al. [34] analyzed the 
 effect of this change in transfusion policy on outcome and found 
a reduction of length of hospital stay from 10.1 to 6.2 days (p < 
0.001) and of mortality from 5.5 to 3.3% (p < 0.001) in transfused 
patients. 
Conclusion
Compensatory mechanisms such as the increase of cardiac out-
put and oxygen extraction allow the human body to tolerate low 
Hb values well. This compensatory capacity is largely maintained 
in patients with cardiovascular diseases and also in the elderly. Pro-
spective randomized studies confirm this conclusion showing that 
liberal Hb transfusion regimens do not offer any outcome benefit 
to high-risk patients but in quite a number of situations inflict 
harm. Scientific evidence thus clearly mandates restrictive Hb 
transfusion triggers also for high-risk patients. Today the best in-
vestigated Hb transfusion trigger for high-risk patients is <70 g/l.
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